Stock Analiz

Ani Pharmaceuticals Inc. (ANIP) financials: revenue, earnings and cash flow

Fiscal 2016–2025 + TTM · from SEC filings · data as of November 13, 2026

Summary

Ani Pharmaceuticals’s revenue went from $129M in fiscal 2016 to $883M in fiscal 2025, growth of about 23.9% a year.

Net income in fiscal 2025 was $78M, a net margin of 8.9%; the highest of the period.

Over the twelve months to September 30, 2026, revenue was $1.0B and net income $117M.

Free cash flow was $171M in fiscal 2025 and positive in 9 of the 10 years shown.

The diluted share count rose 83% over the period (dilution).

Revenue, profit and cash flow by year

Revenue
2016: $129M162017: $177M172018: $202M182019: $207M192020: $208M202021: $216M212022: $316M222023: $487M232024: $614M242025: $883M25$883M
Net income
2016: $4M162017: -$1M172018: $15M182019: $6M192020: -$23M202021: -$43M212022: -$48M222023: $19M232024: -$19M242025: $78M25$78M
Free cash flow
2016: $23M162017: $29M172018: $61M182019: $39M192020: $9M202021: $765000212022: -$40M222023: $110M232024: $48M242025: $171M25$171M
EPS (diluted)
2016: $0.34162017: $-0.09172018: $1.30182019: $0.50192020: $-1.88202021: $-3.40212022: $-3.05222023: $0.85232024: $-1.04242025: $3.3225$3.32

Income statement

Fiscal yearTTM2025202420232022202120202019201820172016
Revenue$1.0B$883M$614M$487M$316M$216M$208M$207M$202M$177M$129M
Gross profit——————$121M$143M$129M$98M$80M
Operating income$166M$111M$584000$47M-$35M-$40M-$16M$16M$35M$28M$20M
Net income$117M$78M-$19M$19M-$48M-$43M-$23M$6M$15M-$1M$4M
EPS (diluted)$5.01$3.32$-1.04$0.85$-3.05$-3.40$-1.88$0.50$1.30$-0.09$0.34
R&D$51M$52M$45M$34M$22M$11M$16M$20M$15M$9M$3M
Revenue growth—+43.8%+26.2%+53.9%+46.4%+3.7%+0.9%+2.5%+14.0%+37.5%+68.5%

Cash flow

Fiscal yearTTM2025202420232022202120202019201820172016
Operating cash flow$229M$185M$64M$119M-$31M$3M$15M$46M$67M$39M$27M
Capital spending-$24M-$14M-$16M-$9M-$9M-$3M-$6M-$7M-$6M-$10M-$5M
Free cash flow$205M$171M$48M$110M-$40M$765000$9M$39M$61M$29M$23M
Dividends paid$0$1M$2M$2M$2M$190000$0$0———
Buybacks$19M$12M$11M$5M$2M$890000$2M$1M$0$0$2M
Stock-based pay$43M$38M$29M$21M$15M$10M$13M$9M$7M$6M$6M

Balance sheet

Fiscal yearTTM2025202420232022202120202019201820172016
Cash—$286M$145M$221M$48M$100M$8M$62M$43M$31M$27M
Debt—$320M$324M$291M$289M$289M$186M$186M$71M$128M$121M
Equity—$541M$404M$433M$314M$334M$196M$213M$197M$175M$170M
Total assets—$1.4B$1.3B$904M$760M$772M$461M$457M$431M$412M$323M
Shares (diluted)22M21M19M18M16M13M12M12M12M12M12M

Margins and returns

Fiscal yearTTM2025202420232022202120202019201820172016
Gross margin——————58.2%69.4%63.8%55.3%62.1%
Operating margin16.0%12.6%0.1%9.7%-11.2%-18.4%-7.7%7.9%17.5%16.0%15.6%
Net margin11.2%8.9%-3.0%3.9%-15.1%-19.7%-10.8%2.9%7.7%-0.6%3.1%
FCF margin19.7%19.4%7.8%22.6%-12.7%0.4%4.4%18.9%30.4%16.4%17.8%
ROIC—10.5%0.1%6.1%-4.5%-4.9%-3.6%3.2%10.2%7.4%5.5%
ROE—14.5%-4.6%4.3%-15.3%-12.8%-11.5%2.9%7.8%-0.6%2.3%

Frequently asked questions

What is Ani Pharmaceuticals’s annual revenue?

$883M in fiscal 2025 and $1.0B over the twelve months to September 30, 2026.

How much profit does Ani Pharmaceuticals make?

Net income was $78M in fiscal 2025 (net margin 8.9%).

Is Ani Pharmaceuticals’s revenue growing?

Yes: revenue rose 43.8% in fiscal 2025 compared with the year before.

From the company’s 10-K and 10-Q filings with the SEC; per-share figures adjusted for stock splits. Rebuilt daily. Not investment advice.